Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Allen, Azar & Troy: FDA Legal Partners Streamline Enforcement Activity

This article was originally published in The Tan Sheet

Executive Summary

HHS' decision to elevate FDA warning letter oversight from the Office of Regulatory Affairs to the Office of the Chief Counsel signals an attempt to keep a tighter rein on the agency in the absence of a commissioner

Related Content

FDA Chief Counsel Bradshaw Brings DoJ Experience
FDA Guidances: Agency Fine Tunes Language, May Undertake Broad Review
Paper Tigers Or Paper Bullets? FDA Cutting Down On Repeat GMP Warnings
FDA GMP Plan Stresses Consistency; Systems Approach Ratified By Crawford
Martek Revenue Could Double, Reach $90 Mil. In FY 2003, CEO Says
FDA Warning Letter Review Suggests Aggressive Action Needed, Troy Says
NDAC Member Wood Joins FDA Commissioner Candidate List
FDA Chief Counsel Troy Brings WLF Experience To Post
FDA Chief Counsel Troy Brings WLF Experience To Post
Ocean Spray Request For Web Site Content Guidance Follows FDA Warning





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts